Charles Schwab’s Enliven Therapeutics ELVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$14.1M Buy
360,577
+5,385
+2% +$149K ﹤0.01% 1933
2025
Q4
$5.47M Sell
355,192
-8,010
-2% -$160K ﹤0.01% 2407
2025
Q3
$7.43M Buy
363,202
+57,542
+19% +$1.16M ﹤0.01% 2261
2025
Q2
$6.13M Buy
305,660
+46,123
+18% +$873K ﹤0.01% 2247
2025
Q1
$5.11M Sell
259,537
-2,351
-0.9% -$50.6K ﹤0.01% 2260
2024
Q4
$5.89M Buy
261,888
+6,611
+3% +$171K ﹤0.01% 2263
2024
Q3
$6.52M Buy
255,277
+24,043
+10% +$557K ﹤0.01% 2235
2024
Q2
$5.4M Buy
231,234
+72,199
+45% +$1.52M ﹤0.01% 2326
2024
Q1
$2.8M Buy
159,035
+595
+0.4% +$9.13K ﹤0.01% 2498
2023
Q4
$2.19M Buy
158,440
+1,809
+1% +$22.1K ﹤0.01% 2589
2023
Q3
$2.14M Buy
156,631
+94,169
+151% +$1.59M ﹤0.01% 2575
2023
Q2
$1.27M Buy
+62,462
New +$1.26M ﹤0.01% 2684
2023
Q1
Sell
-2,880
Closed -$47.1K 3562
2022
Q4
$47.1K Buy
+2,880
New +$46K ﹤0.01% 3372
2021
Q3
Sell
-4,571
Closed -$145K 3515
2021
Q2
$145K Sell
4,571
-3,867
-46% -$120K ﹤0.01% 3280
2021
Q1
$285K Sell
8,438
-349
-4% -$17.7K ﹤0.01% 3257
2020
Q4
$775K Buy
8,787
+810
+10% +$68K ﹤0.01% 2850
2020
Q3
$650K Sell
7,977
-199
-2% -$17.9K ﹤0.01% 2806
2020
Q2
$904K Buy
+8,176
New +$915K ﹤0.01% 2653

Other funds holding ELVN